Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials

Cancer

Volumn 124, Issue 9, 2018, Pages 2010-2017

  Kelly, Karen ^a   Infante, Jeffrey R ^b   Taylor, Matthew H ^c   Patel, Manish R ^d   Wong, Deborah J ^e   Iannotti, Nicholas ^f   Mehnert, Janice M ^g   Loos, Anja H ^h   Koch, Helga ^h   Speit, Isabell ^h   Gulley, James L ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Hematology Oncology Associates of Treasure Coast   (United States)

^g ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^h MERCK KGAA   (Germany)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

avelumab; immunotherapy; JAVELIN; programmed death ligand 1 (PD L1); safety

Indexed keywords

ASPARTATE AMINOTRANSFERASE; AVELUMAB; CORTICOSTEROID; CREATINE KINASE; CYCLOSPORINE; DIPHENHYDRAMINE; EVEROLIMUS; GAMMA GLUTAMYLTRANSFERASE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; PARACETAMOL; PREDNISONE; TACROLIMUS; TRIACYLGLYCEROL LIPASE; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

ADRENAL INSUFFICIENCY; ADVANCED CANCER; ARTICLE; AUTOIMMUNE DISEASE; CANCER MORTALITY; CANCER PATIENT; CHILL; COHORT ANALYSIS; COLITIS; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FATIGUE; FEVER; GUILLAIN BARRE SYNDROME; HEPATITIS; HUMAN; HYPOTHYROIDISM; IMMUNOPATHOLOGY; INFUSION RELATED REACTION; INSULIN DEPENDENT DIABETES MELLITUS; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTICENTER STUDY; MYOSITIS; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POST HOC ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; RASH; RHEUMATOID ARTHRITIS; SIDE EFFECT; SOLID MALIGNANT NEOPLASM; SYMPTOM; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THYROID DISEASE; ADVERSE EVENT; AGED; DISEASE EXACERBATION; DOSE RESPONSE; FEMALE; FOLLOW UP; IMMUNOLOGY; INCIDENCE; INJECTION SITE REACTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NEOPLASM; PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; B7-H1 ANTIGEN; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; INJECTION SITE REACTION; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; TREATMENT OUTCOME;

EID: 85042387648     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.31293     Document Type: Article

References (32)

1. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974-1982.
2. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51-60.
3. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33:2092-2099.
4. Heery CR, O'Sullivan-Coyne G, Madan RA, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18:587-598.
5. Merck KGaA. Bavencio (avelumab) injection [package insert]. Darmstadt, Germany: Merck KGaA; 2017.
6. Merck KGaA. Bavencio (avelumab) injection [summary of product characteristics]. Darmstadt, Germany: Merck KGaA; 2017.
7. Gulley JL, Rajan A, Spigel DR, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol. 2017;18:599-610.
8. Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase 1b study. J Clin Oncol. 2017;35:2117-2124.
9. Chung HC, Arkenau HT, Wyrwicz L, et al. 2364 avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer: a phase 1b trial. Eur J Cancer. 2015;51(suppl 3):S457.
10. Disis ML, Patel MR, Pant S, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase 1b trial: safety and clinical activity. J Clin Oncol. 2016;34:5533.
11. Hassan R, Thomas A, Patel MR, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN Solid Tumor phase 1b trial: safety, clinical activity, and PD-L1 expression. J Clin Oncol. 2016;34:8503.
12. Kelly K, Heery CR, Patel MR, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial. J Clin Oncol. 2016;34:3055.
13. Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374-1385.
14. Kaufman HL, Russell JS, Hamid O, et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018;6:7.
15. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons: 1980.
16. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
17. Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21:4286-4293.
18. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.
19. Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol. 2012;2012:656340.
20. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375-2391.
21. Garon EB, Rizvi NA, Hui R, et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
22. Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34:3119-3125.
23. Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3:1148-1157.
24. Fujii R, Friedman ER, Richards J, et al. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget. 2016;7:33498-33511.
25. Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2:846-856.
26. Sharon E, Streicher H, Goncalves P, Chen HX. Immune checkpoint inhibitors in clinical trials. Chin J Cancer. 2014;33:434-444.
27. Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3:1052-1062.
28. Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist. 2017;22:470-479.
29. Chen R, Peng PC, Wen B, et al. Anti-programmed cell death (PD)-1 immunotherapy for malignant tumor: a systematic review and meta-analysis. Transl Oncol. 2015;9:32-40.
30. Zhang T, Xie J, Arai S, et al. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget. 2016;7:73068-73079.
31. De Velasco G, Je Y, Bosse D, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res. 2017;5:312-318.
32. Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010;14:E10-E21.